Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: A prospective cohort study

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 58-63

  Gallos, Ioannis D ^a   Devey, James ^b   Ganesan, Raji ^c   Gupta, Janesh K ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

Cohort study; Endometrial hyperplasia; Immunohistochemistry; Intrauterine device medicated; LNG IUS; Steroid receptors

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; LEVONORGESTREL; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN MLH1;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RELAPSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; COHORT STUDIES; CYCLOOXYGENASE 2; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84879102196     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.04.016     Document Type: Article

References (34)

1. R.J. Kurman, P.F. Kaminski, and H.J. Norris The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients Cancer 56 1985 403 412
2. S.D. Reed, K.M. Newton, W.L. Clinton, M. Epplein, R. Garcia, and K. Allison Incidence of endometrial hyperplasia Am J Obstet Gynecol 200 2009 678.e1-6
3. I.D. Gallos, O. Ofinran, M. Shehmar, A. Coomarasamy, and J.K. Gupta Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists Eur J Obstet Gynecol Reprod Biol 158 2011 305 307
4. I.D. Gallos, M. Shehmar, S. Thangaratinam, T.K. Papapostolou, A. Coomarasamy, and J.K. Gupta Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis Am J Obstet Gynecol 203 2010 547.e1-10
5. I.D. Gallos, P. Krishan, M. Shehmar, R. Ganesan, and J.K. Gupta Oral progestogens versus LNG-IUS (Mirena®) treatment for endometrial hyperplasia: a long-term comparative cohort study Fertil Steril 2013 (submitted for publication)
6. I.D. Gallos, P. Krishan, M. Shehmar, R. Ganesan, and J.K. Gupta Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long term follow up Hum Reprod 28 2013 1231 1236 10.1093/humrep/det049
7. C.L. Trimble, J. Kauderer, R. Zaino, S. Silverberg, P.C. Lim, and J.J. Burke Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study Cancer 106 2006 812 819
8. W.A. Meissner, S.C. Sommers, and G. Sherman Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen Cancer 10 1957 500 509
9. E. Akesson, I.D. Gallos, R. Ganesan, R. Varma, and J.K. Gupta Prognostic significance of oestrogen and progesterone receptor expression and others in LNG-IUS (Mirena®) treatment of endometrial hyperplasia: an immunohistochemical study Acta Obstet Gynecol Scand 89 2010 393 398
10. K. Watanabe, H. Sasano, N. Harada, M. Ozaki, H. Niikura, and S. Sato Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies Am J Pathol 146 1995 491 500
11. J.M. Fowler, N. Ramirez, D.E. Cohn, N. Kelbick, J. Pavelka, and I. Ben Shachar Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis Am J Obstet Gynecol 192 2005 1262 1271
12. V.H. Jongen, A.V. Sluijmer, and M.J. Heineman The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer Maturitas 43 2002 77 85
13. G. Ferrandina, F. Legge, F.O. Ranelletti, G.F. Zannoni, N. Maggiano, and A. Evangelisti Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome Cancer 95 2002 801 807
14. R.N. Dubois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, and L.B. Van De Putte Cyclooxygenase in biology and disease FASEB J 12 1998 1063 1073
15. R.W. Brueggemeier, B. Su, Y. Sugimoto, E.S. Diaz-Cruz, and D.D. Davis Aromatase and COX in breast cancer: enzyme inhibitors and beyond J Steroid Biochem Mol Biol 106 2007 16 23
16. R. Fujiwaki, K. Iida, H. Kanasaki, T. Ozaki, K. Hata, and K. Miyazaki Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase Hum Pathol 33 2002 213 219
17. C.A. Amezcua, W. Zheng, L.I. Muderspach, and J.C. Felix Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia Gynecol Oncol 73 1999 126 136
18. N. Horowitz, K. Pinto, D.G. Mutch, T.J. Herzog, J.S. Rader, and R. Gibb Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia Gynecol Oncol 86 2002 62 68
19. F. Linkov, R. Edwards, J. Balk, Z. Yurkovetsky, B. Stadterman, and A. Lokshin Endometrial hyperplasia, endometrial cancer and prevention: gaps in existing research of modifiable risk factors Eur J Cancer 44 2008 1632 1644
20. D.Y. Lin, and J.L. Wei The robust inference for the Cox proportional hazards model J Am Stat Assoc 84 1989 1074 1078
21. D.M. Barnes, W.H. Harris, P. Smith, R.R. Millis, and R.D. Rubens Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients Br J Cancer 74 1996 1445 1451
22. I.D. Gallos, and J.K. Gupta The study design and compliance may affect strength of inferences Am J Obstet Gynecol 207 2012 e9 e10
23. J.G. Lijmer, B. Mol, S. Heisterkamp, G.J. Bonsel, M.H. Prins, and J.H. van der Meulen Empirical evidence of design-related bias in studies of diagnostic tests JAMA 282 1999 1061 1066
24. E. Vittinghoff, and C.E. McCulloch Relaxing the rule of ten events per variable in logistic and Cox regression Am J Epidemiol 165 2007 710 718
25. T.J. Clark, D. Voit, J.K. Gupta, C. Hyde, F. Song, and K.S. Khan Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review JAMA 288 2002 1610 1621
26. T.J. Clark, C.H. Mann, N. Shah, K.S. Khan, F. Song, and J.K. Gupta Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia Acta Obstet Gynecol Scand 80 2001 784 793
27. T.J. Clark, C.H. Mann, N. Shah, K.S. Khan, F. Song, and J.K. Gupta Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review BJOG 109 2002 313 321
28. R.K. Hejmadi, S. Chaudhri, R. Ganesan, and T.P. Rollason Morphologic changes in the endometrium associated with the use of the mirena coil: a retrospective study of 106 cases Int J Surg Pathol 15 2 2007 Apr 148 154
29. K. Upson, K.H. Allison, S.D. Reed, C.D. Jordan, K.M. Newton, and E.M. Swisher Biomarkers of progestin therapy resistance and endometrial hyperplasia progression Am J Obstet Gynecol 36 2012 e1 e8
30. C.E. Ehrlich, P.C. Young, and R.E. Cleary Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications Am J Obstet Gynecol 141 1981 539 546
31. B. Lindahl, and R. Willen Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia Anticancer Res 18 1998 3793 3795
32. H. Masuzawa, N.H. Badokhon, K. Nakayama, I. Konishi, T. Nikaido, and S. Fujii Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias Cancer 74 1994 2321 2328
33. I.D. Gallos, R. Ganesan, and J.K. Gupta Prediction of regression and relapse of endometrial hyperplasia treated with LNG-IUS (Mirena®) or oral progestogens: a cohort study Obstet Gynecol 2013 (in press)
34. B. Anderson, J.P. Connor, J.I. Andrews, C.S. Davis, R.E. Buller, and J.I. Sorosky Obesity and prognosis in endometrial cancer Am J Obstet Gynecol 174 1996 1171 1179